Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting.

Inspired by microvesicle-mediated intercellular communication, we propose a hybrid vector for magnetic drug delivery. It consists of macrophage-derived microvesicles engineered to enclose different therapeutic agents together with iron oxide nanoparticles. Here, we investigated in vitro how magnetic nanoparticles may influence the vector effectiveness in terms of drug uptake and targeting. Human macrophages were loaded with iron oxide nanoparticles and different therapeutic agents: a chemotherapeutic agent (doxorubicin), tissue-plasminogen activator (t-PA) and two photosensitizers (disulfonated tetraphenyl chlorin-TPCS2a and 5,10,15,20-tetra(m-hydroxyphenyl)chlorin-mTHPC). The hybrid cell microvesicles were magnetically responsive, readily manipulated by magnetic forces and MRI-detectable. Using photosensitizer-loaded vesicles, we showed that the uptake of microvesicles by cancer cells could be kinetically modulated and spatially controlled under magnetic field and that cancer cell death was enhanced by the magnetic targeting. From the clinical editor: In this article, the authors devised a biogenic method using macrophages to produce microvesicles containing both iron oxide and chemotherapeutic agents. They showed that the microvesicles could be manipulated by magnetic force for targeting and subsequent delivery of the drug payload against cancer cells. This smart method could provide a novel way for future fight against cancer.

[1]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[2]  T. Pellegrino,et al.  Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials. , 2013, Nanoscale.

[3]  Rebecca C Taylor,et al.  Apoptosis: controlled demolition at the cellular level , 2008, Nature Reviews Molecular Cell Biology.

[4]  Lianbo Yu,et al.  Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.

[5]  C Alexiou,et al.  Clinical applications of magnetic drug targeting. , 2001, The Journal of surgical research.

[6]  Victor C Yang,et al.  Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. , 2010, Biomaterials.

[7]  M. Senge,et al.  Temoporfin (Foscan®, 5,10,15,20‐Tetra(m‐hydroxyphenyl)chlorin)—A Second‐generation Photosensitizer †,‡ , 2011, Photochemistry and photobiology.

[8]  Photophysical and photobiological properties of a sulfonated chlorin photosensitiser TPCS(2a) for photochemical internalisation (PCI). , 2013, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[9]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[10]  H. Mojzisova,et al.  Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells , 2007, European Biophysics Journal.

[11]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Dongmei Sun,et al.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  J. Rosenecker,et al.  Insights into the mechanism of magnetofection using PEI‐based magnetofectins for gene transfer , 2004, The journal of gene medicine.

[14]  Luigi Biancone,et al.  Exosomes/microvesicles as a mechanism of cell-to-cell communication. , 2010, Kidney international.

[15]  T. Park,et al.  A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Florence Gazeau,et al.  Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. , 2006, Radiology.

[17]  S. Lesieur,et al.  Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. , 2007, Radiology.

[18]  Eleanor Stride,et al.  Magnetic targeting and ultrasound mediated drug delivery: Benefits, limitations and combination , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[19]  Shuming Nie,et al.  Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.

[20]  Lutz Trahms,et al.  Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[21]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Zhi-Feng Gan,et al.  A novel magnetic fluid based on starch-coated magnetite nanoparticles functionalized with homing peptide , 2009 .

[23]  H Anholt,et al.  Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. , 1999, Cancer research.

[24]  K. Janes,et al.  Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  M. Wood,et al.  Exosomes for targeted siRNA delivery across biological barriers. , 2013, Advanced drug delivery reviews.

[26]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[27]  J. Freyssinet,et al.  Membrane microparticles: two sides of the coin. , 2005, Physiology.

[28]  Miqin Zhang,et al.  Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. , 2010, Advanced drug delivery reviews.

[29]  C. Alexiou,et al.  Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.

[30]  K. Widder,et al.  Magnetic guidance of drug‐carrying microspheres , 1978 .

[31]  D. Pisetsky,et al.  The role of microparticles in the pathogenesis of rheumatic diseases , 2010, Nature Reviews Rheumatology.

[32]  L. Horstman,et al.  Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. , 2003, Thrombosis research.

[33]  Gunther Hartmann,et al.  SiRNA delivery with exosome nanoparticles , 2011, Nature Biotechnology.

[34]  Vincent Dupuis,et al.  Ultra magnetic liposomes for MR imaging, targeting, and hyperthermia. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[35]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[36]  T. Galli,et al.  Glutamate Controls tPA Recycling by Astrocytes, Which in Turn Influences Glutamatergic Signals , 2012, The Journal of Neuroscience.

[37]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[38]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[39]  J Henke,et al.  Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo , 2002, Gene Therapy.

[40]  Christian Bergemann,et al.  Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. , 2008, Biomaterials.

[41]  Crislyn D'Souza-Schorey,et al.  Microvesicles: mediators of extracellular communication during cancer progression , 2010, Journal of Cell Science.

[42]  J Ratajczak,et al.  Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication , 2006, Leukemia.

[43]  S. Kadam,et al.  Plasminogen activators: a comparison. , 2006, Vascular pharmacology.

[44]  Wing-Cheung Law,et al.  Phospholipid micelle-based magneto-plasmonic nanoformulation for magnetic field-directed, imaging-guided photo-induced cancer therapy. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[45]  C. Santilli,et al.  Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. , 2006, Colloids and surfaces. B, Biointerfaces.

[46]  Alaa A. A. Aljabali,et al.  CPMV-DOX delivers. , 2013, Molecular pharmaceutics.

[47]  Patrick Couvreur,et al.  Fe3O4/chitosan nanocomposite for magnetic drug targeting to cancer , 2012 .

[48]  C. Wilhelm,et al.  The role of cell-released microvesicles in the intercellular transfer of magnetic nanoparticles in the monocyte/macrophage system. , 2010, Biomaterials.

[49]  P Reichardt,et al.  Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.

[50]  M. Bureau,et al.  Magnetic and photoresponsive theranosomes: translating cell-released vesicles into smart nanovectors for cancer therapy. , 2013, ACS nano.